Merck May Need New Arcoxia Trial Design Prior To FDA Approval
Executive Summary
Merck may need to conduct additional Arcoxia clinical trials to gain FDA approval after the agency and its COX-2 inhibitor advisory committee cited flaws in the existing program
You may also be interested in...
Merck Arcoxia MEDAL Results Will Likely Not Meet FDA Gold Standard
Despite the release of positive results from a long-term cardiovascular safety trial of its Vioxx follow-on Arcoxia, Merck will likely need to conduct additional studies before receiving FDA approval of the COX-2 inhibitor
Merck Arcoxia MEDAL Results Will Likely Not Meet FDA Gold Standard
Despite the release of positive results from a long-term cardiovascular safety trial of its Vioxx follow-on Arcoxia, Merck will likely need to conduct additional studies before receiving FDA approval of the COX-2 inhibitor
Mobic May Gain Momentum After Bextra Withdrawal
Boehringer Ingelheim's non-steroidal anti-inflammatory drug Mobic may be poised to emerge as a blockbuster product following the market withdrawal of Pfizer's COX-2 inhibitor Bextra